Bank Of America Corp Moleculin Biotech, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.41 - $0.86 $15 - $32	38 Added 38.0%	138 $0
Q2 2023 Aug 14, 2023	SELL	$0.54 - $0.95 $3,591 - $6,317	-6,650 Reduced 98.52%	100 $0
Q1 2023 May 12, 2023	BUY	$0.9 - $1.34 $60 - $89	67 Added 1.0%	6,750 $6,000
Q4 2022 Feb 10, 2023	BUY	$0.85 - $16.65 $28 - $549	33 Added 0.5%	6,683 $7,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $17.4 $19 - $295	-17 Reduced 0.25%	6,650 $7,000
Q2 2022 Aug 12, 2022	BUY	$1.19 - $2.0 $20 - $34	17 Added 0.26%	6,667 $9,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.9 $62 - $96	-51 Reduced 0.76%	6,650 $12,000
Q4 2021 Feb 08, 2022	BUY	$1.64 - $2.83 $83 - $144	51 Added 0.77%	6,701 $12,000
Q3 2021 Nov 15, 2021	SELL	$2.7 - $3.59 $32 - $43	-12 Reduced 0.18%	6,650 $20,000
Q2 2021 Sep 13, 2021	BUY	$3.21 - $4.06 $21,385 - $27,047	6,662 New	6,662 $24,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.